UMB Bank’s BridgeBio Pharma BBIO Stock Holding History

UMB Bank’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.72K	Buy	50 +17	+52%	+$1.19K	﹤0.01%	2133
2026 Q1	$2.45K	Hold	33	–	–	﹤0.01%	2140
2025 Q4	$2.52K	Hold	33	–	–	﹤0.01%	2149
2025 Q3	$1.71K	Buy	+33	New	+$1.61K	﹤0.01%	2056

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

UMB Bank's BBIO Position: Q2 2026 in Review

UMB Bank increased its BridgeBio Pharma (BBIO) stake by 52% in Q2 2026, buying an estimated $1.19K and bringing the position to 50 shares worth $3.72K. The position accounts for ﹤0.01% of the portfolio, ranked #2133.

UMB Bank first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

UMB Bank held 50 shares of BridgeBio Pharma worth $3.72K as of Q2 2026.
UMB Bank bought 17 BridgeBio Pharma shares in Q2 2026, an estimated $1.19K.
BridgeBio Pharma made up ﹤0.01% of UMB Bank's portfolio in Q2 2026, its #2133 holding.
UMB Bank first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on UMB Bank's 13F filing for Q2 2026, filed 13 Aug 2026.